Most of these articles paid more attention to whether a particular drug could modify the target signaling pathway to decrease the abnormal production of pro-inflammatory cytokines and alleviate RA instead of studying the pathways that might be influenced, such as the mTOR pathway. This evidence concerns the gene MTOR and rheumatoid arthritis.